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FLUDARABINE BASED CONDITIONING REGIMEN FOR ALLOGENEIC
STEM CELL TRANSPLANTATION FOR MULTIPLY TRANSFUSED PA-
TIENTS WITH FANCONI’S ANEMIA
George, B., Mathews, V., Srivastava, A., Chandy, M. Department of
Haematology, Christian Medical College, Vellore, Tamil Nadu, India.
Multiply transfused patients with severe aplastic anemia or Fan-
coni’s anemia (FA) have an increased risk of graft rejection after
allogeneic stem cell transplantation (SCT) which can be as high as
30%. Intense immunosuppression in the conditioning regimen is
therefore required which is achieved by high doses of cyclophos-
phamide and addition of antithymocyte globulin (ATG). Since
such dosages of cyclophosphamide cannot be administered to pa-
tients with FA, we have evaluated ﬂudarabine based conditioning
regimen for SCT in these patients.
Three children with FA underwent allogeneic SCT using ﬂu-
darabine based conditioning regimen. All donors were HLA
matched sibling or parents. Conditioning regimen consisted of
ﬂudarabine (30 mg/m2/day for 6 days), cyclophosphamide (10mg/
kg/day for 2 days) and ATG (ATGAM 10 mg/kg/day for 4 days).
All were males with a mean age of 12 years (range: 8-15). The
median time from diagnosis to BMT was 32 months (range:18-54)
with the average number of red cell transfusions being 25 (range:
15-40). Two patients received G-CSF stimulated bone marrow
while one received G-CSF stimulated PBSC. The regimen was
well tolerated with no major toxicities. All patients engrafted with
the average time to ANC  500/mm3 being 15 days (range: 13-17)
and time to unsupported platelet count 20,000/mm3 being 17
days (range: 15-18). None of the patients developed acute graft
versus host disease. One patient developed secondary graft rejec-
tion on day 59 and expired on day 72 due to fungal pneumonia.
Chimerism analysis using VNTR on day 60 showed a pattern
consistent with rejection. Other 2 patients are well and in complete
remission(CR) with a median follow up of 12 and 26 months.
Optimal conditioning regimens for patients with multiply trans-
fused FA remains to be deﬁned. Addition of ﬂudarabine to the
conditioning regimen for SCT in FA can provide additional im-
munosuppression for engraftment without increasing toxicity.
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PATIENTS WITH SEVERE APLASTIC ANEMIA CAN BE ALLOGRAFTED
SUCCESFULLY WITHOUT ANTI-THYMOCYTE GLOBULIN, USING A NON-
MYELOABLATIVE CONDITIONING REGIMEN
Go´mez-Almaguer, D.1, Vela-Ojeda, J.2, Jaime-Pe´rez, J.C.1, Gutie´r-
rez-Aguirre, C.H.1, Cantu´-Rodrı´guez, O.G.1, Go´mez-Rangel, D.3,
Ruiz-Argu¨elles, G.J.3 1. Hospital Universitario UANL, Monterrey,
Nuevo Leo´n, Mexico; 2. Centro Me´dico La Raza IMSS, Me´xico, DF,
Mexico; 3. Centro de Hematologı´a y Medicina Interna, Puebla, Puebla,
Mexico.
Introduction: We investigated the effectivity of ﬂudarabine-
cyclophosphamide based conditioning regimen without ATG or
lymph node irradiation in 16 SAA heavily transfused patients stud-
ied in three different medical centers in Me´xico. The patients have
had no response to previous pharmacologic conventional treat-
ment, including androgens and immunosuppressive therapy. Ma-
terial and Methods: The SAA patients were included in three
conditioning groups, 5 cases received oral busulphan 4mg/kg/day/
2days, CY 350mg/m2/day/3days and ﬂudarabine 30/mg/m2/day/3
days, in the second group (ﬁve cases) no busulphan was used and
CY, 45mg/kg/day/2 days was given. In the third group, ﬂudarabine
50mg/day/5days and CY 1.5g/m2/day/3 days were utilized. For
GVHD prophylaxis cyclosporine and methotrexate was used. For
infection prophylaxis the patients received ciproﬂoxacin, ﬂucon-
azole and acyclovir. All the patients received peripheral blood stem
cells from their HLA identical siblings. The donors were stimu-
lated with G-CSF 10/Kg/4 days. Results: the age range was 4 to
51 years. The peripheral blood stem cell product was infused in 1-3
days, with a median dose of 7.1 x106 CD34/kg. The patients were
followed for a median of 24 months (range,4 to 77). At a median of
day 12 an ANC 0.5x109/L was reached, and also the platelet
count reached 20,000x109/L at the same day. Acute grade I-II
GVHD occurred in 2 patients, whereas limited chronic GVHD
presented in 3 cases. Ten patients (62%) achieved sustained en-
graftment and are currently in clinical remission. Two patients
failed to engraft and 4 failed to achieved sustained engraftment; 2
of these individuals died as a result of the graft failure, 2 survive
with high transfusion requirements, whereas 2 received a second
transplant using the same donor and conditioning regimen, and
achieved sustained engraftment. Currently 14/16 patients are alive,
whereas 12/16 (75%) remain in a complete remission. Discussion:
These ﬂudarabine based conditioning regimens have acceptable
toxicity, low cost and allows durable engraftment, representing a
viable alternative to traditional more citotoxic conditioning for
SAA patients who receive a stem cell allograft.
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IMMUNOSUPPRESSION WITH ATG F ALLOWS FOR SUCCESSFUL TRANS-
PLANTATION FROM MISMATCHED UNRELATED DONORS
Zander, A.R., Zabelina, T., Ayuk, F., Kabisch, H., Erttmann, R., Fehse,
N., Fehse, B., Wolschke, C., Stute, N., Kratochwille, A., Panse, J.,
Eiermann, T.H., Kroger, N.M. Bone Marrow Transplantation Centre,
University of Hamburg, Hamburg, Germany.
Allogeneic bone marrow transplantation of matched unrelated
donors carries an increased risk of Graft-versus-Host-Disease and
transplant related mortality. We introduced ATG Fresenius [me-
dian dose 90mg/kg bw] as part of the conditioning for prevention
of serious GvHD. We compared 48 patients with mismatched
transplant with 170 patients with an HLA matched transplant. The
mismatch involved of 1 or 2 loci. The groups differed in age. HLA
match 33y (0,9-61), HLA mismatch 21y (0,9-51), and graft source
BM vs. PBSC 67/33% in match vs. 83/17% in mismatch.
They were comparable in diagnoses, stage of disease and condi-
tioning. Conclusion: Addition of ATG Fresenius permits hemo-
poietic stem cell transplantation from mismatched donors with
results comparable [regarding GvH control, TRM and survival] to
HLA matched donors.
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A HIGH THROUGHPUT SNP BASED KIR GENOTYPING SYSTEM FOR USE
IN ALLOGENEIC TRANSPLANTATION AND OUTCOMES ANALYSES
Houtchens, K.A., Nichols, R.J., Boal, H.E., Herman, T.M., Trachten-
berg, E.A. Children’s Hospital Oakland Research Institute, Oakland,
CA.
Recent evidence suggests that interactions between an individu-
al’s Killer Immunoglobulin-like Receptor (KIR) molecular proﬁle
and Human Leukocyte Antigen (HLA) ligands may play an im-
portant role in stem cell transplant outcome (Ruggerri et al., Science
2002; Gagne et al., Human Immunology 2002). If these early results
are replicated, it may be necessary to assess KIR genotypes as part
of the donor selection process. Like the HLA genes, the KIR genes
are highly polymorphic. As the characterization of the total diver-
sity of these genes is still in its infancy, novel variants are reported
frequently. We are developing a novel, high-throughput single
nucleotide polymorphism (SNP)-based KIR genotyping method-
ology. In this assay, the nucleic acid mass differences generated in
a SNP-based primer extension reaction are analyzed on a matrix-
assisted laser desorption/ionization time-of-ﬂight mass spectrom-
eter (MALDI-TOF). The method uses 384-well microarray chips,
and is by nature both highly accurate and rapid. More importantly
Table.
Results HLA Match HLA Mismatch P
GvHD 2–4 43% 33% 0,2
GvHD 3–4 22% 10% 0,06
Chronic GvHD 38% 38% 0,9
5 year DFS 45% 51% 0,5
Overall survival 50% 51% 0,7
TRM 33% 25% 0,2
Relapse rate 5 years 31% 30% 0,6
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this method is capable of identifying novel polymorphisms as well
as recognizing polymorphisms that have already been identiﬁed as
informative for distinguishing the various alleles. When fully de-
veloped the method will be two-tiered i.e., capable of resolving
KIR genotypes with locus-speciﬁcity or at an allele-speciﬁc level of
resolution. We present data from previously characterized control
DNA samples and transplant samples using this novel typing
method to demonstrate that the method is capable of accurately
deﬁning KIR genotypes.
74
REDUCED INTENSITY PERIPHERAL BLOOD STEM CELL TRANSPLANT
FROM MATCHED RELATED AND UNRELATED DONORS FOR POOR RISK
HEMATOLOGICAL MALIGNANCY
Rossetti, J.M., Lieb, J.V., Shadduck, R.K., Gryn, J.F., Lister, J. West-
ern Pennsylvania Cancer Institute, Pittsburgh, PA.
46 patients with advanced, poor risk hematological malignancy
underwent conditioning with Fludarabine 120 mg/m2, Melphalan
140-180 mg/m2 and Ethyol 910 mg/m2 (FME) followed by periph-
eral blood stem cell transplant (PBSCT) from matched sibling
(sib-allo) (n  25) or matched unrelated donor (MUD) (n  21).
Average age was 46 years (range 19-65). Graft versus host disease
(GVHD) prophylaxis consisted of mycophenolate mofetil 1 gram
q12h through day 35 and dosage adjusted tacrolimus to a target
trough serum level of 5-15 ng/ml through day 90. At 30 days (n 
46) transplant related mortality (TRM) was11%, overall survival
(OS) was 89%, and relapse mortality (RM) was 0%. At 100 days
(n 45) TRM was 40%, OS was 51%, and RM was 9%. The most
frequent causes of death at day 100 were acute GVHD, disease
relapse, and adult respiratory distress syndrome. White blood cell
engraftment was achieved in 98% of patients in an average of 13
days (range 9-21). This engraftment was achieved and maintained
without the use of donor lymphocyte infusion (DLI). One patient
died at day 24 without engrafment. Platelet engraftment was
achieved in 80% of patients in an average of 18 days. In one patient
the platelet count never declined below 20 k/L. Eight patients
died prior to platelet engraftment. All evaluable patients showed
95% donor marrow cells at 100 days after transplant. Acute
GVHD incidence for patients not receiving DLI and alive more
than 30 days after transplant was 56% (grade 2  1, 3  17, 4 
4). For patients more than one year after transplant (n  33) the
OS was 30% (sib-allo  37%, MUD  21%) and disease free
survival was 18% (sib-allo  21%, MUD  14%).
In this aged, heavily pretreated, poor risk group of patients,
reduced intensity PBSCT using FME can yield short-term sur-
vival. This regimen provided rapid and durable engraftment with
full donor hematopoiesis in a majority of patients without the need
for DLI. In an effort to reduce the incidence of acute GVHD and
hopefully TRM, we have added thymoglobulin to the conditioning
regimen at 2 mg/kg/day to be given on days -2, -1, and 0. The
impact on OS, DFS, and chronic GVHD remains to be deter-
mined.
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INTRAVENOUS BUSULFAN VERSUS MELPHALAN-BASED LOW INTEN-
SITY CONDITIONING PRIOR TO ALLOGENEIC STEM-CELL TRANSPLAN-
TATION: LOWER TRM AND A MORE FAVORABLE TOXICITY PROFILE
Shimoni, A.1, Hardan, I.1, Yeshurun, M.1, Avigdor, A.1, Papatrypho-
nos, A.2, Tsolakis, F.I.3, Nagler, A.1 1. Chaim Sheba Medical Center,
Tel-Hashomer, Israel; 2. Archbishop Makarios III, Nicosia, Cyprus; 3.
Limassol General Hospital, Limassol, Cyprus.
Low intensity conditioning (LIC) regimens have been designed
to reduce the toxicity associated with allogeneic stem-cell trans-
plantation (SCT) and to allow SCT in elderly, heavily pretreated
and medically inﬁrm patients. However, the toxicity associated
with some of these regimens is still substantial and it is currently
unknown whether any of the regimens has advantage over the
others. We compared the toxicity and 1-year treatment related
mortality (TRM) following two LIC regimens: ﬂudarabine and
intravenous busulfan (FivBu) (total intravenous Busulfan dose 6.4
mg/kg) and ﬂudarabine and melphalan (FM) (total melphalan dose,
100-140 mg/m2). Fludarabine dose was 125-150 mg/m2 in both
regimens. Ninety-ﬁve patients with various hematologic malignan-
cies (52% chemo-refractory) not eligible for standard condition-
ing, were included in the study. Forty-nine patients (52%) had a
prior autologous SCT. The median age was 52 years (range, 20-66
years). Fifty-three patients had FM and 42 had FivBu. The donor
was an HLA-matched sibling (n  63) or a matched unrelated
donor (n  32). With a median follow-up of 10 months (range,
1-38) 55 patients are alive. Twenty patients (21%) have died due to
TRM. TRM occurred in 4 patients (10%) and 16 patients (30%)
within 1 year following FivBu and FM, respectively. The estimated
Kaplan-Meyer TRM risk was 11  5% and 33  7%, respectively
(p  0.02). The univariant analysis also identiﬁed a prior autolo-
gous SCT within 1 year of the current SCT (p  0.02) and
diagnosis of lymphoma (p  0.05) as risk factors for TRM. Age,
donor source, and chemo-sensitivity were not signiﬁcant. When
these variables were included in a multivariable Cox regression
model the hazard ratios for TRM for patients conditioned with
FM, patients with a prior SCT and patients with lymphoma were
3.2 (1.1-9.6; p 0.04), 2.5 (1.0-6.0; p 0.05) and 2.2 (0.9-5.3; p
0.08), respectively. Severe mucositis and organ dysfunction were
more common after FM, while neutropenia duration was shorter
after FivBu. In conclusion, FivBu has a more favorable toxicity
proﬁle and relatively low TRM as RIC for SCT and may prove to
be the preferred LIC regimen. Disease-speciﬁc studies are required
to assess the impact of different conditioning regimens on relapse
rate, and whether reduction of TRM will translate to better dis-
ease-free survival.
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CYCLOPHOSPHAMIDE, TOTAL BODY IRRADIATION (TBI) AND MAB-
CAMPATH (ALEMTUZUMAB) AS CONDITIONING FOR VOLUNTARY UN-
RELATED DONOR (VUD) HAEMOPOIETIC STEM CELL TRANSPLANTS
(HSCT): THE SCOTTISH EXPERIENCE
Bhandari, S., Walker, M., Holyoake, T., Franklin, I.M., McQuaker,
G., Parker, A.N. Glasgow Royal Inﬁrmary, Glasgow, Scotland, United
Kingdom.
Scotland has a population of approximately 5 million people and
supports a single VUD allograft centre based in Glasgow. We
adopted a conditioning regime consisting of 60 mg/kg cyclophos-
phamide D-6 to D-5, TBI 1440 Gy in 8 fractions D-4 to 0 and
Mabcampath 10 mg D-5 to -1 in year 2000. Data was collected
retrospectively in 9/03 for the 21 VUD HSCT patients (pts)
conditioned with this regime between 4/00 and 4/03. 11 males and
10 females were transplanted for the following diagnoses; 12 AML
(7CR1, 5CR2), 4 ALL (2CR1, 2CR2), 4 MDS and 1 NHL (CR2).
The median age was 31 years (range 17-50). Molecular tissue
typing carried out at the A, B, Cw, DRB1 and DQ loci matched at
all 10 loci in 17 pts. 3 pts mismatched at class 2 (2DRB1;1DQ) and
1 mismatched at 2 loci (DRB1 and Cw). 12 pts received unmodiﬁed
bone marrow median dose 3.2x108 mononuclear cells/kg (range 1
to 6.7x 108) and 9 had peripheral blood stem cells median dose
7x106 CD34/kg (range 1.4 to 12x106). All received short course
methotrexate and cyclosporine as graft versus host disease (GvHD)
prophylaxis, which was tapered from D100 if there was no acute
GvHD. Median follow up was 647 days (range 170 to 1233 days).
The median time to neutrophil engraftment 0.5x109/l was 17 days
(range 13 to 29 days) and platelets 20x 109/l was 17 days (range
11 to 32 days). There were no graft failures. Acute grade II-IV
GvHD occurred in 5 pts (23.8%) with grade II in 3 (14.3%) and
grade III in 2 (9.5%). No grade IV acute GVHD was seen. Of the
5 acute GvHD pts, 1 died of disease relapse, 2 died of post
transplant lymphoproliferative disorder (PTLD), 1 developed
chronic extensive GvHD (grade III pt) and 1 had complete reso-
lution of acute GvHD. Relapse occurred in 5 pts (24%). The D100
transplant related mortality (TRM) was 14.3% and at 3.4 years the
overall survival was 48% and TRMwas 33%. There were 11 (52%)
deaths in total, 4 due to disease relapse, 4 infection, 2 PTLD and
1 haemorrhage.
The incidence of grade II-IV acute GVHD is low supporting the
use of Mabcampath as an effective anti-GvHD agent. The two
cases of PTLD were surprising given that Mabcampath depletes
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